272 related articles for article (PubMed ID: 27105565)
1. Altered interaction and distribution of glycosaminoglycans and growth factors in mucopolysaccharidosis type I bone disease.
Kingma SDK; Wagemans T; IJlst L; Bronckers ALJJ; van Kuppevelt TH; Everts V; Wijburg FA; van Vlies N
Bone; 2016 Jul; 88():92-100. PubMed ID: 27105565
[TBL] [Abstract][Full Text] [Related]
2. Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities.
Wilson S; Hashamiyan S; Clarke L; Saftig P; Mort J; Dejica VM; Brömme D
Am J Pathol; 2009 Nov; 175(5):2053-62. PubMed ID: 19834056
[TBL] [Abstract][Full Text] [Related]
3. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.
Opoka-Winiarska V; Jurecka A; Emeryk A; Tylki-Szymańska A
Osteoarthritis Cartilage; 2013 Dec; 21(12):1813-23. PubMed ID: 23954699
[TBL] [Abstract][Full Text] [Related]
4. Delayed hypertrophic differentiation of epiphyseal chondrocytes contributes to failed secondary ossification in mucopolysaccharidosis VII dogs.
Peck SH; O'Donnell PJ; Kang JL; Malhotra NR; Dodge GR; Pacifici M; Shore EM; Haskins ME; Smith LJ
Mol Genet Metab; 2015 Nov; 116(3):195-203. PubMed ID: 26422116
[TBL] [Abstract][Full Text] [Related]
5. Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.
Kingma SD; Wagemans T; IJlst L; Wijburg FA; van Vlies N
J Inherit Metab Dis; 2014 Sep; 37(5):813-21. PubMed ID: 24699889
[TBL] [Abstract][Full Text] [Related]
6. Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII.
Rowan DJ; Tomatsu S; Grubb JH; Montaño AM; Sly WS
J Inherit Metab Dis; 2013 Mar; 36(2):235-46. PubMed ID: 22971960
[TBL] [Abstract][Full Text] [Related]
7. Ultrastructural analysis of different skeletal cell types in mucopolysaccharidosis dogs at the onset of postnatal growth.
Jiang Z; Lau YK; Wu M; Casal ML; Smith LJ
J Anat; 2021 Feb; 238(2):416-425. PubMed ID: 32895948
[TBL] [Abstract][Full Text] [Related]
8. Sulfated glycosaminoglycans mediate the effects of FGF2 on the osteogenic potential of rat calvarial osteoprogenitor cells.
Ling L; Murali S; Dombrowski C; Haupt LM; Stein GS; van Wijnen AJ; Nurcombe V; Cool SM
J Cell Physiol; 2006 Dec; 209(3):811-25. PubMed ID: 16972247
[TBL] [Abstract][Full Text] [Related]
9. Extracellular matrix disruption is an early event in the pathogenesis of skeletal disease in mucopolysaccharidosis I.
Heppner JM; Zaucke F; Clarke LA
Mol Genet Metab; 2015 Feb; 114(2):146-55. PubMed ID: 25410057
[TBL] [Abstract][Full Text] [Related]
10. Growth impairment in mucopolysaccharidoses.
Melbouci M; Mason RW; Suzuki Y; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2018 May; 124(1):1-10. PubMed ID: 29627275
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of failed endochondral ossification in mucopolysaccharidosis VII.
Peck SH; Tobias JW; Shore EM; Malhotra NR; Haskins ME; Casal ML; Smith LJ
Bone; 2019 Nov; 128():115042. PubMed ID: 31442675
[TBL] [Abstract][Full Text] [Related]
12. Altered IHH signaling contributes to reduced chondrocyte proliferation in the growth plate of MPS VII mice.
Jiang Z; Derrick-Roberts ALK; Byers S
Mol Genet Metab Rep; 2020 Dec; 25():100668. PubMed ID: 33117654
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of shortened bones in mucopolysaccharidosis VII.
Metcalf JA; Zhang Y; Hilton MJ; Long F; Ponder KP
Mol Genet Metab; 2009 Jul; 97(3):202-11. PubMed ID: 19375967
[TBL] [Abstract][Full Text] [Related]
14. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T
Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019
[TBL] [Abstract][Full Text] [Related]
15. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
Entchev E; Jantzen I; Masson P; Bocart S; Bournique B; Luccarini JM; Bouchot A; Lacombe O; Junien JL; Broqua P; Tallandier M
PLoS One; 2020; 15(5):e0233032. PubMed ID: 32413051
[TBL] [Abstract][Full Text] [Related]
16. Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity.
Baldo G; Tavares AM; Gonzalez E; Poletto E; Mayer FQ; Matte UD; Giugliani R
Cardiovasc Pathol; 2017; 27():45-50. PubMed ID: 28104572
[TBL] [Abstract][Full Text] [Related]
17. Hepatic storage of glycosaminoglycans in feline and canine models of mucopolysaccharidoses I, VI, and VII.
Haskins ME; Otis EJ; Hayden JE; Jezyk PF; Stramm L
Vet Pathol; 1992 Mar; 29(2):112-9. PubMed ID: 1632054
[TBL] [Abstract][Full Text] [Related]
18. Morphological damage in Sertoli, myoid and interstitial cells in a mouse model of mucopolysaccharidosis type I (MPS I).
do Nascimento CC; Aguiar O; Viana GM; D'Almeida V
Mol Biol Rep; 2021 Jan; 48(1):363-370. PubMed ID: 33319323
[TBL] [Abstract][Full Text] [Related]
19. Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs.
Mango RL; Xu L; Sands MS; Vogler C; Seiler G; Schwarz T; Haskins ME; Ponder KP
Mol Genet Metab; 2004 May; 82(1):4-19. PubMed ID: 15110316
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.
Derrick-Roberts A; Kaidonis X; Jackson MR; Liaw WC; Ding X; Ong C; Ranieri E; Sharp P; Fletcher J; Byers S
Mol Genet Metab; 2020; 131(1-2):197-205. PubMed ID: 32739280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
